Steven R. DeMeester, M.D.
disclosures–22 sec
BE incidence–30 sec https://www.ncbi.nlm.nih.gov/pubmed/15366737
HGD–1:18
issues to consider–2:25
endotherapy candidates–2:44
low risk submucosal invasion–3:31 https://www.
Keyword(s): AIM II, BE, cryospray ablation, CSA Medical, depth of invasion, EGD, en-bloc resection, endoscopic resection, endoscopic tx, endotherapy, esophageal adenocarcinoma, esophagectomy, EUS, Halo 360, HGD, IM, intramucosal cx, lap Nissen, LGD, LN metastases, NBI, reflux, RFA, surveillance, UE, VSE
Comments are closed.